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Abstract—Objective: To determine the inter-rater reliability of a modification of the Memorial Sloan-Kettering (MSK)
Staging for HIV-associated cognitive impairment. Methods: Data were abstracted on neurologic, neuropsychological, and
functional status on 100 individuals participating at four sites in the Northeast AIDS Dementia (NEAD) Consortium
cohort study, a longitudinal study of predictors of cognitive impairment in HIV-infected individuals. Neuropsychological
performance was defined 1) based on the neuropsychologist’s global impression and 2) solely based on neuropsychological
test scores. Raters at each site used the abstracted data to assign an MSK stage to each subject blind to any identifying
information. Inter-rater reliability was assessed using kappa statistics. Agreement between computer-generated ratings
and site-generated ratings was also assessed. Results: Kappa statistics for pair-wise agreement among the sites regarding
MSK stage ranged from 0.70–0.91, representing good to excellent agreement between sites. Agreement between
computer-generated ratings and site-generated ratings was in the good to excellent range (0.62–0.79). Conclusions: The
authors have modified the MSK rating scale and developed a reliable instrument that can be used in multicenter studies.
This instrument will be useful in staging HIV-dementia in future longitudinal studies and will be valuable in increasing
accuracy of clinicopathologic studies.
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In February 1998, the Northeast AIDS Dementia
(NEAD) Consortium was created to recruit a cohort
of individuals at high risk for the development of
HIV-dementia (HIV-D). This cohort was initially es-
tablished at three sites: Columbia University, Johns
Hopkins University, and the University of Rochester.
In 1999, a site at Northwestern University was
added. Inclusion and exclusion criteria for this new
cohort were identical to those used in a previous
collaboration, the Dana Consortium on Therapy for
HIV Dementia and Related Cognitive Disorders, es-
tablished in February 1994.1
One of the primary aims of the Dana Consortium
was to determine predictors of the development of
HIV-D, including HIV-Associated Minor Cognitive
Motor Disorder (MCMD). To uniformly diagnose both
HIV-D and MCMD across sites, we developed a com-
puterized algorithm to operationalize the criteria
proposed by the American Academy of Neurology in
1991.2 These operationalized criteria were then used
to define HIV-D and MCMD in 272 individuals in the
Dana cohort.1 In longitudinal analyses, over a
follow-up period of up to 30 months, we examined
factors associated with time to develop HIV-D.3
The Memorial Sloan Kettering (MSK) Staging of
the AIDS dementia complex8 was devised in 1988 in
order to “establish a common vocabulary for epidemi-
ologic, natural history, and therapy studies with cri-
teria that are reasonably easy to establish based on
the clinical examination and that do not require spe-
cial expertise in neuropsychological testing.” It has
been used in clinical trials4-7 and in a cohort study.1
The stages from 0 (normal) to 4 (end stage) are dif-
ferentiated primarily by degree of functional impair-
ment in activities including work and self-care and
also by mobility status. Details on specific neurologic
and neuropsychological abnormalities are not specif-
ically delineated. In an attempt to standardize the
interpretation of these ratings, we operationalized
the definitions of each MSK stage using information
from neurologic and neuropsychological examina-
tions and functional assessments and then assessed
the inter-rater reliability of this algorithm across
four sites participating in the NEAD cohort.
Subjects. To be included in the NEAD cohort,
subjects had to be HIV-positive, and have either a
CD4 cell count below 200/L or a CD4 count below
300/L with cognitive impairment on a neuropsycho-
logical test battery. Exclusion criteria were 1) cur-
rent or past opportunistic CNS infection at study
entry with the exception of treated neurosyphilis
prior to diagnosis of HIV, 2) history or current clini-
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cal evidence of schizophrenia, and 3) history of
chronic neurologic disorders such as MS or uncon-
trolled epilepsy. Current alcohol or drug use were
not grounds for exclusion.
Assessments. Clinical assessments were per-
formed every 6 months for up to 48 months. At each
visit, subjects underwent a medical history, a stan-
dardized neurologic examination, a neuropsychologi-
cal battery, functional and psychiatric assessments,
and a blood draw for laboratory studies including
viral load and immune activation markers. CSF was
collected every 12 months.
Neurologic examination. The neurologic exami-
nation was designed to detect signs associated with
HIV-D. The macro-neurologic examination created
for the AIDS Clinical Trials Group and the motor
subscale (Part III) of the Unified PD Rating Scale
(UPDRS)9 were performed by examiners who were
videotaped to ensure reliable administration, after
reviewing a teaching tape. Items specifically men-
tioned in the MSK staging (e.g., snout, slowed ex-
tremity movements) (table 1) as well as other signs
indicative of either minimal or unequivocal motor
dysfunction were used to derive the neurologic scores
used in the new MSK algorithm.
Neuropsychological examination. The neuropsy-
chological battery was designed to delineate HIV-D
and MCMD. The eight tests included in the core
neuropsychological battery covered six domains. Ver-
bal memory was assessed with the Rey Auditory Ver-
bal Learning Test.10 Visual memory was assessed
with the Rey-Osterrieth Complex Figure Delayed Re-
call Test.10 Constructional skills were assessed with
the Rey-Osterrieth Complex Figure Immediate Re-
call Test.10 Psychomotor skills were measured with
the Digit Symbol Test.11 Motor skills were assessed
with the Grooved Pegboard (dominant and nondomi-
nant hand)12 and timed gait tests. Frontal systems
were assessed with Verbal Fluency13 and the Odd-
Man-Out tests.14,15 Reaction time was measured with
Table 1 Clinical staging of HIV dementia: NEAD classification
MSK Stage* New criteria: NEAD modification Characteristics
Stage 0 (normal) NP impression  0
EVEN IF cognitive complaints are present
Normal mental and motor function
No IADL functional impairments
Stage 0.5 (subclinical or
equivocal)
1) NP impression  0 AND any CNS neuro
findings OR any IADL functional
impairment
2) NP impression  1 AND no IADL
functional impairment
Either minimal/equivocal symptoms or motor
dysfunction characteristic of HIV-D, or mild
neurological signs (eg snout, slowed extremity
movements), but without impairment of work or
capacity to perform ADL.
Stage 1 (mild HIV-D) 1) NP impression is 1 AND abnormalities in
both CNS neurological exam AND IADL
function
2) NP impression is 2 BUT no abnormalities
in EITHER CNS neuro exam OR IADL
function
Able to perform all but the more demanding aspects
of work or ADL but with unequivocal evidence
(has to include abnormal NP performance) of
functional, intellectual or motor impairment
AND
Can walk without assistance.
Stage 2 (moderate HIV-D) 1) NP impression is 2 AND any abnormalities
in EITHER CNS neuro exam OR IADL
function
2) NP impression is 2 AND mild to moderate
abnormalities in BOTH CNS neuro exam
AND IADL function, however neither
severe
Able to perform basic activities of self-care but
cannot work or maintain the more demanding
aspects of daily life.
AND
Ambulatory, but may require a single prop or cane.
Stage 3 (severe HIV-D) 1) NP impression is 2 AND severe
abnormalities in CNS neuro exam AND
IADL function
2) NP impression is 2 AND mild to moderate
abnormalities in CNS neuro exam AND
severe IADL functional impairment AND
severe gait impairment
3) NP impression is 3 AND gait is mild to
moderately impaired
Major intellectual incapacity (cannot follow news or
personal events, cannot sustain complex
conversation, considerable slowing of all outputs)
OR
motor disability (cannot walk unassisted, requiring
walker or personal support, usually with slowing
and clumsiness of arms as well).
Stage 4 (very severe/end
stage HIV-D)
1) Unable to perform NP testing because of
cognitive-motor impairments
2) unable to walk on CNS basis
Nearly vegetative. Intellectual and social
comprehension and output are at a rudimentary
level. Nearly or absolutely mute.
Paraparetic or paraplegic with urinary and fecal
incontinence.
NP impression may be the neuropsychologist’s global cognitive impression or the quantitative global neuropsychological impression.
* Developed at Memorial Sloan Kettering Center.8
ADL  activities of daily living; IADL  instrumental activities of daily living.
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the California Computerized Assessment package
(CALCAP).16 Scores for subjects with 12 years of
education were compared with norms established by
the AIDS Link to IV Experience (ALIVE)17 cohort,
whereas scores of subjects with 12 years of educa-
tion were compared with norms established by the
Multicenter AIDS cohort study.18 Cognitive impair-
ment sufficient to meet study enrollment criteria
was defined as performance 2 SDs below the appro-
priate mean on one test, or 1 SD below the mean on
two tests. If timed gait was the only measure on
which subjects scored 2 SDs below the mean, sub-
jects were not considered to have met cognitive im-
pairment criteria.
The neuropsychological battery was administered
at each site by a trained neuropsychometrician. The
neuropsychologist at each site assigned a global neu-
ropsychological impression (normal, mild, moderate,
or severe) to each subject. The exception was for
subjects at the Northwestern site, for whom this
global impression rating was assigned by the neuro-
psychologist at Johns Hopkins because there was no
participating neuropsychologist at the Northwestern
site. For this rating, a summary of individual neuro-
psychological subtest raw scores as well as age and
education adjusted z-scores for each subject was
used. The rating was based on the overall gestalt of
the test scores, taking into account specific factors
such as the estimated pre-morbid IQ (NART), as well
as the number and specific cognitive domains im-
paired for each subject. For all sites, the rating was
based on the actual neuropsychology test scores
without any interaction with the subject.
In addition, a separate algorithm was created to
generate a quantitative global neuropsychological
impression (table 2). Eight tests yielded 12 subtest
scores that were used to generate the quantitative
neuropsychological rating (see table 2).
Functional measures. Functional measures were
chosen that would reflect the degree to which cogni-
tive deficits compromised everyday function, a re-
quirement for the diagnoses of HIV-D and MCMD.
Measures were derived from the Instrumental Activ-
ities of Daily Living (IADL) scales of Lawton and
Brody,19 the Katz Instrumental Activities of Daily
Living/Lawton Personal Self-Maintenance Scale,20
and the role functioning items of the Medical Out-
comes Study.21 Two functional outcomes that reflect
stress and stamina were also included: the Karnof-
sky performance scale22 and the Medical Outcomes
Study physical function subscale.21 To meet the min-
imal functional deficit criterion for the MSK staging,
respondents were required to report deficits in at
least one of the eight IADL (e.g., using telephone,
handling money, taking medication, doing laundry,
light housework, preparing meals, shopping for gro-
ceries, getting to places beyond walking distance).
Psychiatric assessment. The Beck depression in-
ventory23 was administered to assess depressive
symptoms. This is a 21-item self-report scale that is
considered the standard to which other self-report
depression scales are compared. Depression items
are not included in the MSK; however, in forming
their global neuropsychological impression, neuro-
psychologists considered the impact of depression on
cognitive impairment.
Modification of the MSK rating system. Over a
3-year period, investigators in the NEAD Consor-
tium met three times to determine which items from
the clinical assessments would be included in the
modified MSK staging, and to determine how the
assessments would be used to assign an MSK stage.
For example, it was decided that peripheral neurop-
athy would not be considered as a neurologic abnor-
mality in the MSK rating whereas myelopathy and
any CNS abnormality would. Specific scores on each
of the items were chosen as cutoffs for defining
abnormalities.
In the neurologic domain, a three-tier categoriza-
tion was developed (no, mild, or severe abnormality)
based on the neurologist’s evaluation of oculomotor,
motor, and extrapyramidal signs (EPS). Twelve CNS
neurologic signs were included within these three
larger categories.
“Normal” status required that subjects show no
deficits in ocular motility (smooth pursuit, saccades),
strength and coordination, and reflexes and no EPS.
“Mild” status assignment required “mild to moderate
abnormality” on any one of the same indicators. “Se-
vere” status required that subjects meet criteria for
extrapyramidal deficits along with deficits in ocular
motility or motor signs. Subjects met the EPS crite-
rion if they had any abnormality on the UPDRS.
Subjects met the motor domain criterion if they
scored in the abnormal range in upper or lower ex-
Table 2 Algorithm for determining quantitative global
impression of cognitive function
NP domain Test Subtest
Verbal memory Rey Auditory Verbal Trial 5
Learning Test Delayed recall
Delayed recognition
Visual memory Rey Complex Figure Delayed recall
Visuoconstruction Rey Complex Figure Copy
Frontal/executive Odd-Man-Out (Total score)
Verbal fluency (Total score)
Psychomotor Digit symbol (Total score)
CALCAP Choice
Sequential
Motor speed Grooved pegboard Dominant
Nondominant
A score 1 SD below the appropriate norm earns 1 point, and a
score 2 SDs below the appropriate norm earns 2 points; thus,
the range of the summary impairment score is 0–24. A summary
impairment score of (0–1)  quantitative global impression of 0
(normal); (2–6)  quantitative global impression of 1 (mild);
(7–14)  quantitative global impression of 2 (moderate); and
(15–24)  a quantitative global impression of 3 (severe).
NP  neuropsychological; CALCAP  California Computerized
Assessment Package.
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tremity strength or coordination. Subjects met the
oculomotor criterion if they showed abnormalities in
smooth pursuit or saccades.
A similar approach was developed for the function
and ambulation domains. For example, mild func-
tional deficit required that subjects report a need for
help with no more than two household tasks or at
least one of the broad role competency indicators
(i.e., report of inability to perform tasks carefully).
Severe functional deficit required that subjects re-
port a need for help with three or more household
tasks. Functional impairment had to be attributed to
CNS rather than peripheral nervous system (PNS)
abnormalities. At the investigator meetings that led
to the development of the algorithm, each of the sites
examined data from randomly selected cases and
modifications to the rating system were made based
on discussions of disagreements. This process contin-
ued until all sites were rating cases similarly and
investigators agreed upon a formal algorithm for as-
signing MSK stages (see table 1).
Subjects were assigned an MSK stage according to
severity of deficit in four dimensions: neuropsycho-
logical performance, neurologic status, self-rated
function, and ambulation. For example, one chal-
lenge was to differentiate “normal” (MSK 0), “sub-
clinical or equivocal” deficit (MSK 0.5), and “mild
HIV-D” (MSK 1). Subjects were assigned MSK 0 if
their cognitive performance was in the normal range
and they also had no deficits in neurologic, func-
tional, or ambulation status. Subjects were assigned
MSK 0.5 if they had no or mild cognitive impairment
but abnormalities in either the neurologic or func-
tional domain. Subjects were assigned MSK 1 if they
had mild cognitive impairment and abnormalities in
both neurologic and functional domains, or if they
had moderate cognitive impairment but no other ab-
normalities. In this way, MSK scores were consis-
tently assigned based on combinations of severity
across the four dimensions. These distinctions
emerged from our understanding of the original
scale, clinical experience regarding the significance
of the deficit types, and the empirical co-occurrence
of deficits in the cohort.
Design of the inter-rater reliability study. The
data necessary to arrive at an MSK rating, from the
neurologic, neuropsychological, and functional as-
sessments, were obtained from 25 NEAD cohort sub-
jects at each of the four sites (100 patients in all). All
data were collected on standard case report forms at
each site and abstracted directly from these case re-
port forms onto a standardized single-page form by
individuals who were not involved in the rating pro-
cess. These forms were sent to the central data coor-
dination center (Rochester, NY) where subject and
site identifiers were removed, and the complete set of
100 forms was sent to each of the four sites. At each
site the investigators, including at least one neurolo-
gist and one neuropsychologist, provided consensus
MSK ratings based on the abstracted data and the
algorithm (see table 1). Two ratings for each form
were provided; one that used the neuropsychologist’s
global impression of cognitive functioning that was
directly abstracted onto the data form, and a second
that instead used the quantitative global impression
of cognitive functioning (see table 2).
In addition, a SAS program (SAS Institute, Inc.,
Cary NC) was written to implement the algorithm in
table 1 so that a modified MSK rating could be
computer-generated from the information in the
NEAD database. To classify individual subjects, the
information in the database was grouped into four
domains: neurologic, neuropsychological (the quanti-
tative global impression of cognitive functioning de-
rived in table 2), functional, and mobility. The degree
of abnormalities in each domain was used to com-
pute the MSK rating. Whether functional or mobility
impairments were due to CNS or peripheral nervous
system (PNS) abnormalities was not captured in the
computerized ratings.
Statistical analysis. Weighted kappa statistics24
were used to assess the inter-rater reliability for all
six possible pairs of sites for each of the two MSK
ratings that were generated. Weighted kappa statistics
were also used to assess the agreement between each
site’s MSK rating (using the quantitative global im-
pression of cognitive functioning) and the computer-
generated MSK rating.
Results. The percentages of individuals rated at each stage ac-
cording to the abstracted global NP impression and the quantita-
tive global neuropsychological impression at each site are shown
in table 3. Intersite agreement for MSK ratings is shown in table
4. Weighted kappa values are in the good to excellent range24 with
the majority being in the excellent range (0.75). In general,
investigators at Columbia and Northwestern rated subjects as
slightly less impaired than investigators at Johns Hopkins and
Rochester. The weighted kappa values were similar for MSK rat-
ings derived from the neuropsychologist’s global impression and
the quantitative neuropsychologist’s impression. The agreement
between computer-generated MSK scores and clinician consensus
ratings at each of the sites was also in the good to excellent range.
Discussion. We have shown that by operationaliz-
ing the criteria proposed in the MSK, first described
in 1988 as the “Clinical Staging of the AIDS Demen-
tia Complex,”4 we were able to achieve good to excel-
lent reliability among investigators at four sites
using either the neuropsychologist’s global impres-
sion of cognitive function or a quantitative neuropsy-
chological impression based solely on test scores. We
then demonstrated good to excellent reliability be-
tween a completely computerized algorithm that in-
cluded a quantitative neuropsychological impression
and the MSK ratings at each site.
Although scores must be reviewed to eliminate
impairments that clearly predate HIV infection, the
creation of a computerized algorithm may be useful
in epidemiologic studies and clinical trials, particu-
larly those that involve multiple sites, providing an
outcome measure that is less encumbered by individ-
ual judgments by investigators. However, the algo-
rithm is only as good as the data collected, and the
presumption that standardized assessments are be-
ing performed is implicit in determining whether
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this exercise translates into true reliability in the
field. We have tried to ensure standardized adminis-
tration of all aspects of the exams by using training
manuals, videotapes, and frequent case discussions
among examiners to hone definitions. This study did
not assess reliability among examiners based on actual
patient observation, testing, and scoring. Rather, the
study assessed the reliability of determining clinical
stage of cognitive impairment based on abstracted
data. It may also be difficult in a computerized algo-
rithm to capture the nuances in mobility. While indi-
viduals with distal sensory polyneuropathy were not
considered neurologically impaired according the algo-
rithm, the contribution that the neuropathy made to
gait and functional impairment could not be completely
captured in the algorithm.
It is also clear that even with experienced investi-
gators an intensive effort is required to test and re-
fine definitions when using categorical and
subjective scales. Only after three full-day meetings
over a 3-year period were the investigators interpret-
ing non-quantified or semi-quantified ratings simi-
larly. At that time, table 1 was created to reflect the
collective thinking of the investigators. A computer-
ized algorithm cannot substitute for this ongoing
training, and should be employed only when consen-
sus has been achieved.
Inter-rater reliability for diagnosis of dementia.
Inter-rater reliability of clinical diagnostic criteria
for a number of neurodegenerative dementing disor-
ders has been examined. The use of clinical diagnos-
tic criteria for neurodegenerative diseases has
improved inter-rater reliability and accuracy in clin-
icopathological studies. The American Psychiatric
Association diagnostic criteria from the Diagnostic
and Statistical Manual (DSM III-R),25 National Insti-
tute of Neurological Disorders and Stroke-ADRDA,26
the Eisdorfer and Cohen Research Diagnostic Crite-
ria (ECRDC), and ICD-10 diagnostic criteria for AD
have been assessed separately27,28 and compared.29,30
Inter-rater reliability of the Lund Manchester crite-
ria for frontotemporal dementia,31 the Consensus
Guidelines for the Clinical Diagnosis of Dementia
with Lewy Bodies (DLB)32,33 and the National Insti-
tute of Neurologic Disorders and Stroke (National
Institute of Neurological Disorders and Stroke) and
the Association Internationale pour la Recherche et
l’Enseignement en Neurosciences (AIREN)34 diagnos-
tic criteria for vascular dementia has been assessed.
In general, when data are abstracted and the same
information is provided to raters with similar train-
ing, and research diagnostic criteria are applied for
Table 3 Percentages of individuals at each site rated at each MSK stage using Abstracted NP impression and calculated NP impression
Site Columbia, % Johns Hopkins, % Rochester, % Northwestern, %
Abstracted Global NP Imp
MSK 0 20.7 11.0 12.7 26.8
MSK 0.5 43.9 44.0 49.4 41.5
MSK 1 26.8 23.0 24.0 23.2
MSK 2 8.5 18.0 11.4 7.3
MSK 3 0 4.0 2.5 1.2
Quantitative Global NP Imp
MSK 0 16.2 9.0 9.5 21.0
MSK 0.5 39.4 42.0 42.1 36.0
MSK 1 22.2 19.0 20.0 24.0
MSK 2 21.2 26.0 24.2 18.0
MSK 3 1.0 4.0 4.2 1.0
MSK  Memorial Sloan Kettering; NP  neuropsychological.
Table 4 Weighted kappa and percent agreement for MSK ratings





Columbia-Johns Hopkins 0.79 76.8
Columbia-Univ Rochester 0.78 75.8
Columbia-Northwestern 0.81 78.8
Univ Rochester-Johns Hopkins 0.87 86.3
Univ Rochester-Northwestern 0.74 71.6
Johns Hopkins-Northwestern 0.71 69.0
Quantitative global NP impression
Columbia-Johns Hopkins 0.74 78.0
Columbia-Univ Rochester 0.73 76.9
Columbia-Northwestern 0.77 76.3
Univ Rochester-Johns Hopkins 0.91 92.4
Univ Rochester-Northwestern 0.74 73.4
Johns Hopkins-Northwestern 0.70 70.7
Site vs computer-generated
Computer-Columbia 0.70 67.0
Computer-Johns Hopkins 0.77 75.3
Computer-Univ Rochester 0.79 75.5
Computer-Northwestern 0.62 56.7
NP  neuropsychological.
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specific diseases, kappa statistics are in the good to
excellent range. Inter-rater reliability may be de-
creased in situations where a second potential cause
of dementia exists (e.g., AD and vascular disease)34
and modest for Dementia with Lewy bodies,31 per-
haps because of the overlap in clinical criteria with
AD.
Inter-rater reliability in HIV-related studies.
Although several quality of life measures have been
shown to be reliable and valid in studies of HIV-
infected individuals,35,36 little has been published on
the reliability of the neurologic examination or neu-
rologic rating scales. Inter-rater reliability was as-
sessed among three experienced neurologists on 20
subjects participating in a natural history study of
HIV-infected individuals.37 Reliability was in the
good-to-excellent range for examination of mentation
and cranial nerve function and in the fair-to-good
range for pyramidal tract signs, cerebellar signs,
sensory, and extrapyramidal signs. Overall agree-
ment (intraclass correlation) on a summary measure
of neurologic function, the modified Kurtzke score,
was 0.89. The inter-rater agreement of a modifica-
tion of the Karnofsky Performance scale was as-
sessed in 657 HIV-infected individuals, and found to
be strong (0.82) between two physicians and slightly
less between a nurse and a physician (0.77).38
The importance of continued training and consen-
sus building in creating an algorithm for staging
HIV-D cannot be underestimated. This has led to the
development of a computerized algorithm that may
prove useful in multicenter clinical trials and obser-
vational studies of HIV-associated cognitive impair-
ment. A reliable instrument is necessary for future
clinicopathologic studies in which diagnostic accu-
racy will be assessed.
Appendix: Members of the NEAD Consortium
Columbia University: Karen Marder, MD, MPH; Yaakov Stern, PhD;
Steven Albert, PhD; George Todak, MSW; Ronda Clouse, RN; Jose Beltre,
BA; Ivan Simonetti, BA. Johns Hopkins University: Ned Sacktor, MD; Ola
Selnes, PhD; Deneen Esposito, BA; Ruby Agoha, BA; David Burgess, MA;
Jason Creighton, BA; Justin McArthur, MBBS, MPH. University of Roches-
ter: Giovanni Schifitto, MD; Michael McDermott, PhD; Donna Palumbo,
PhD; Connie Orme, BA; Larry Preston, BPS; Keith Bourgeois, BS; Kim
Cruttenden, MS; Karl Kieburtz, MD, MPH. Northwestern University: Leon
G. Epstein, MD; Bruce A. Cohen; Linda Reisberg, RN.
References
1. The Dana Consortium on Therapy for HIV Dementia and Related Cog-
nitive Disorders. Clinical confirmation of the American Academy of
Neurology algorithm for HIV-1-associated cognitive/motor disorder.
Neurology 1996;47:1247–1253.
2. Janssen RS, Cornblath DR, Epstein LG, et al. Nomenclature and re-
search case definitions for neurological manifestations of human immu-
nodeficiency virus type-1 (HIV-1) infection. Report of a Working Group
of the American Academy of Neurology AIDS Task Force Neurology
1991;41:778–785.
3. Stern Y, McDermott MP, Albert S, et al. Factors associated with inci-
dent human immunodeficiency virus-dementia. Arch Neurol 2001;58:
473–479.
4. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:
1079–1083.
5. The Dana Consortium on Therapy for HIV Dementia and Related Cog-
nitive Disorders. A randomomized, double-blind, placebo-controlled
trial of deprenyl and thioctic acid in human immunodeficiency virus-
associated cognitive impairment. Neurology 1998;50:645–651.
6. The Dana Consortium on Therapy for HIV Dementia and Related Cog-
nitive Disorders. Safety and tolerability of the antioxidant OPC-14,
117in HIV associated cognitive impairment. Neurology 1999;49:142–
146.
7. Schifitto G, Sacktor N, Marder K, et al. Randomized trial of the
platelet-activating factor antagonist lexipafant in HIV-associated cogni-
tive impairment. Neurological AIDS Research Consortium. Neurology
1999;53:391–396.
8. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC,
Kieburtz K. Transdermal selegiline in HIV-associated cognitive impair-
ment: pilot, placebo-controlled study. Neurology 2000;54:233–235.
9. Fahn S, Marsden C, Calne D. Recent Developments in Parkinson’s
disease. Florham Park: Macmillan Healthcare Information, 1987.
10. Rey A. L’examen psychologique dans les cas d’encephalopathie trauma-
tique. Arch Psychologie 1941;28:286–340.
11. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: The
Psychological Corporation, 1981.
12. Klove H. Clinical neuropsychology. Med Clin North Am 1963;46:1647–
1658.
13. Benton AL, Hamsher KD. Multilingual Aphasia Examination. Iowa
City: University of Iowa, 1976.
14. Flowers KA, Robertson C. The effects of Parkinson’s disease on the
ability to maintain a mental set. J Neurol Neurosurg Psychiatry 1985;
48:517–529.
15. Richards M, Cote LJ, Stern Y. Executive function in Parkinson’s dis-
ease: set-shifting or set- maintenance? J Clin Exp Neuropsychol 1993;
15:266–279.
16. Miller EN, Satz P, Visscher B. Computerized and conventional neuro-
psychological assessment of HIV-1 infected homosexual men. Neurology
1991;41:1608–1616.
17. Selnes OA, Jacobson L, Machado AM, et al. Normative data for a brief
neuropsychological screening battery. Percept Mot Skills 1991;73:539–
550.
18. Concha M, Selnes OA, McArthur J, et al. Normative data for a brief
neuropsychologic test battery in a cohort of injecting drug users. Intl J
Addictions 1995;30:823–841.
19. Lawton MP, Brody EM. Assessment of older people: self-maintaining
and instrumental activities of daily living. Gerontologist 1969;9:179–
186.
20. Katz S, Ford A, Moskowitz R, et al. Studies of illness in the aged: the
index of ADL. JAMA 1963;183:914–919.
21. Stewart AL, Ware JE. Measuring function and well-being: The Medical
Outcomes Study Approach. Durham: Duke University Press, 1993.
22. Karnofsky DA, Abelman WH, Carver LF, et al. The use of nitrogen
mustards in the palliative treatment of carcinoma. Cancer 1948;1:634–
656.
23. Beck AT, Steer R, Brown J. BDI-II Manual. San Antonio: The Psycho-
logical Corp., 1996.
24. Fleiss JL. Statistical Methods for Rates and Proportions. New York:
John Wiley & Sons Inc., 1981.
25. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders, rev. 3rd ed. Washington: American Psychiatric Press
Inc, 1987.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan
EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-
ADRDA Work Group. Neurology 1984;34:939–944.
27. Lopez OL, Swihart AA, Becker JT, et al. Reliability of NINCDS-ADRDA
clinical criteria for the diagnosis of Alzheimer’s disease. Neurology
1990;40:1517–1522.
28. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF.
Reliability and validity of NINCDS-ADRDA criteria for Alzheimer’s
disease. The National Institute of Mental Health Genetics Initiative
Archives of Neurology 1994;51:1198–1204.
29. Kukull WA, Larson EB, Reifler BV, Lampe TH, Yerby M, Hughes
J. Interrater reliability of Alzheimer’s disease diagnosis. Neurology
1990;40:257–260.
30. Baldereschi M, Amato MP, Nencini P, et al. Cross-national interrater
agreement on the clinical diagnostic criteria for dementia. WHO-PRA
Age-Associated Dementia Working Group, WHO-Program for Research
on Aging, Health of Elderly Program. Neurology 1994;44:239–242.
31. Lopez OL, Litvan I, Catt KE, et al. Accuracy of four clinical diagnostic
criteria for the diagnosis of neurodegenerative dementias. Neurology
1999;53:1292–1299.
32. McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the
predictive validity and inter-rater reliability of clinical diagnostic crite-
ria for senile dementia of Lewy body type. Neurology 1994;44:872–877.
33. Mega MS, Masterman DL, Benson DF, et al. Dementia with Lewy
bodies: reliability and validity of clinical and pathologic criteria. Neu-
rology 1996;47:1403–1409.
34. Lopez OL, Larumbe MR, Becker JT, et al. Reliability of NINDS-AIREN
clinical criteria for the diagnosis of vascular dementia [see comments].
Neurology 1994;44:1240–1245.
1472 NEUROLOGY 60 May (1 of 2) 2003
35. Wu A, Rubin H, Mathews W, et al. A health status questionnaire using
30 items from the Medical Outcomes Study. Med Care 1991;29:786–
798.
36. Bozzette SA, Hays RD, Berry SH, Kanouse DE. A Perceived Health
Index for use in persons with advanced HIV disease: derivation, reli-
ability, and validity. Med Care 1994;32:716–731.
37. Marder K, Liu X, Stern Y, et al. Neurologic signs and symptoms in a
cohort of homosexual men followed for 4.5 years. Neurology 1995;45:
261–267.
38. Fantoni M, Izzi I, Del Borgo C, et al. Inter-rater reliability of a modified
Karnofsky Scale of Performance Status for HIV-infected individuals.
AIDS Patient Care & Stds 1999;13:23–28.
Age at focal epilepsy onset varies by sex
and hemispheric lateralization
M.J. Doherty, MD; S. Jayadev, MD; J.W. Miller, MD, PhD; D.F. Farrell, MD; M.D. Holmes, MD; and
C.B. Dodrill, PhD
Abstract—Background: Previous studies have shown that interictal epileptiform discharges favor the left hemisphere in
adults but the right side in children up until age 5. This may be due to sex-influenced asymmetric brain maturation. To
clarify this relationship, the authors analyzed age at epilepsy onset by sex and by lateralization of epileptiform activity.
Methods: An adult epilepsy center long-term monitoring database was used to define patients with exclusively unilateral
epileptiform findings. Three groups were studied: any epileptiform activity (n  404), ictal activity (n  287), and
interictal activity (n  265). The second and third groups were drawn from the first group and the second and third groups
overlapped with each other. Side of lateralized finding and sex were analyzed via factorial two-way analysis of variance
with the outcome variable being age at epilepsy onset. Comparison analysis included patients with generalized epilepsy
(n  114), nonepileptic seizures (NES, n  232), and surgical mesial temporal sclerosis (MTS, n  116). Results: Patients
with unilateral epileptiform activity displayed bimodal epilepsy onset ages with infant and adolescent peaks. For patients
with a right-sided focus, epilepsy onset was earlier in men (14.4 years) than women (20.7 years). In contrast, among
patients with a left-sided focus, epilepsy began earlier in women (18.2 years) than men (19.9 years, p  0.01). Parallel
results were found in unilateral ictal (p  0.01) and unilateral interictal activity (p  0.01). Patients with surgical MTS,
NES, or generalized seizure showed no similar patterns. Conclusions: In adult patients with focal epilepsy, sex and
lateralized epileptiform abnormalities may be related to age at epilepsy onset.
NEUROLOGY 2003;60:1473–1477
In adults, focal interictal epileptiform discharges
(ED) show a preference for the left hemisphere.1-4 In
contrast, children show interictal favoring of right
hemispheric ED until age 5, after which left hemi-
spheric ED become more frequent.5 Because normal
brain maturation and development occurs asym-
metrically at differing rates and times, age-related
hemispheric favoring of ED might reflect age-specific
brain asymmetries.6-10 Sex influences brain asymme-
try and maturation but has yet to be extensively
correlated with lateralization of ED and age at epi-
lepsy onset.11-15 In this study we test the hypothesis
that among adults with focal epilepsy, age at epi-
lepsy onset varies according to both sex and lateral-
ization of ED.
Methods. We studied 1,215 consecutive first scalp long-term
video-EEG monitoring (LTM) database entries. Three exclusively
unilateral groups were defined: Group 1 (n  404) included pa-
tients with ictal or interictal ED. Group 2 (n  289) displayed only
ictal discharges. Group 3 (n  284) demonstrated interictal spike
or sharp wave activity. Groups 2 and 3 were subsets of Group 1.
Lateralization of ED was determined by electroencephalographers
blind to study objectives. Multifocal unilateral ictal, interictal, or
secondarily generalized activities were studied. Combinations of
bilateral ictal or interictal activity, including primary generalized
activity, were excluded. LTM performed on patients 18 years
were excluded, as were invasive or follow-up studies.
Group 4 was defined from a separate database: patients diag-
nosed pathologically with mesial temporal sclerosis (MTS, n 
116). Forty-three Group 4 patients overlapped with Group 1. The
LTM database was used to define Group 5 (n  114) patients with
generalized epilepsy, and Group 6 (n  232) patients with LTM
demonstration of both nonepileptic seizures (NES) and absent ED.
Age at epilepsy onset was defined as the age, in years, during
which repeated, spontaneous, nonfebrile seizures first occurred.
Statistical testing was performed using SPSS (Chicago, IL).
Groups 1 through 3 were analyzed for whether sex and hemi-
spheric lateralization of electrical discharges influenced age at
first seizure using two-way factorial analysis of variance
(ANOVA). For Group 4, surgical MTS, side of surgical resection
was used as the lateralization variable. Supplemental t-test anal-
ysis on Group 1 by sex or hemispheric abnormality clarified un-
derlying effects not evident from ANOVA. Subsets of Group 1
defined by handedness, a family history of seizure, prior neuro-
logic insult (such as birth injury, head trauma, brain tumor,
stroke, meningitis, or encephalitis), or antecedent febrile seizure
were analyzed similarly to Groups 1 through 3. Duration between
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